argenx
TLDR
argenx is a NASDAQ-listed Belgian biotech company headquartered in Ghent, developing antibody-based therapeutics for severe autoimmune diseases.
Overview
Founded in 2008 and listed on NASDAQ and Euronext Brussels, argenx is one of Belgium's most successful biotech companies by market capitalization. The company focuses on developing treatments for severe autoimmune diseases using its proprietary antibody technology platform, SIMPLE Antibody. Its lead product, efgartigimod, is approved in multiple markets for myasthenia gravis and several other indications.
See also
FounderHans de Haard
FounderTorsten Dreier
FounderTim Van Hauwermeiren
LocationGhent
RelatedBrussels
RelatedAgomAb Therapeutics
RelatedGalapagos
RelatedUCB
RelatedOnno van de Stolpe
RelatedAnnie Vereecken
RelatedTim Knotnerus
RelatedAgomAb Therapeutics IPO 2026
Recent news
- Beursupdate: weinig stijgers in BrusselKnack · 24 Apr 2026
- Living with Sjogren’s disease often means navigating symptoms others can’t see. For many, a diagnosis follows years of delayed recognition, invisible symptoms, and daily challenges extending far beyonLinkedIn · 22 Apr 2026
- Living with Sjogren’s disease often means navigating symptoms others can’t see. For many, a diagnosis follows years of delayed recognition, invisible symptoms, and daily challenges extending far beyonLinkedIn · 22 Apr 2026